{"description":"Documents matching 'eptifibatide'","count":31,"total_pages":2,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=eptifibatide&format=json&page=2","results":[{"title":"Determination That AVC (Sulfanilamide) Vaginal Cream, 15%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.","document_number":"2022-17056","html_url":"https://www.federalregister.gov/documents/2022/08/09/2022-17056/determination-that-avc-sulfanilamide-vaginal-cream-15-and-other-drug-products-were-not-withdrawn","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-08-09/pdf/2022-17056.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-17056.pdf?1659962726","publication_date":"2022-08-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":" \n NDA 020593 \n DEPACON \n Valproate Sodium \n 100 mg Base/Milliliter (mL) \n Injectable; Injection \n AbbVie Inc. \n \n \n NDA 020615 \n DURACLON \n Clonidine Hydrochloride \n 5 mg/10 mL (0.5 mg/mL) \n Injectable; Injection \n Mylan Institutional. \n \n \n NDA 020718 \n INTEGRILIN \n <span class=\"match\">Eptifibatide</span> \n 2 mg/mL; 75 mg/100 mL \n Injectable; Injection \n Merck Sharp Dohme. \n \n \n NDA 021005 \n SOLARAZE \n Diclofenac Sodium \n 3% \n Gel; Topical \n Fougera Pharms. \n \n \n NDA 021085 \n AVELOX \n Moxifloxacin Hydrochloride \n EQ 400 mg Base \n Tablet; Oral \n Bayer Healthcare. \n \n \n NDA"},{"title":"Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is withdrawing approval of 18 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.","document_number":"2021-25111","html_url":"https://www.federalregister.gov/documents/2021/11/18/2021-25111/discovery-therapeutics-llc-et-al-withdrawal-of-approval-of-18-abbreviated-new-drug-applications","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-11-18/pdf/2021-25111.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-25111.pdf?1637156723","publication_date":"2021-11-18","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Release Tablets, 500 mg and 750 mg \n Rouses Point Pharmaceuticals, LLC, 11 Commerce Dr., Cranford, NJ 07016. \n \n \n ANDA 202857 \n Daptomycin Powder for Injection, 500 mg/vial \n Hospira, Inc. \n \n \n ANDA 203885 \n Amiodarone HCl Injection, 50 mg/mL \n Do. \n \n \n ANDA 207864 \n <span class=\"match\">Eptifibatide</span> Injection, 2 mg/mL and 75 mg/100 mL \n The WhiteOak Group, LLC, U.S. Agent for Hybio Pharmaceutical Co., Ltd., 1629 K St. NW, Suite 300, Washington, DC 20006. \n \n \n ANDA 209489 \n Caspofungin Acetate Powder for Injection, 50 mg/vial and 70 mg/vial \n Cipla USA, Inc., U.S"},{"title":"Fresenius Kabi USA, LLC, et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is withdrawing approval of 15 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.","document_number":"2021-16047","html_url":"https://www.federalregister.gov/documents/2021/07/28/2021-16047/fresenius-kabi-usa-llc-et-al-withdrawal-of-approval-of-15-abbreviated-new-drug-applications","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-07-28/pdf/2021-16047.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-16047.pdf?1627389937","publication_date":"2021-07-28","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"4310, Morgantown, WV 26504. \n \n \n ANDA 091652 \n Hydrochlorothiazide and Losartan Potassium Tablets, 12.5 mg/50 mg, 12.5 mg/100 mg, and 25 mg/100 mg \n Do. \n \n \n ANDA 204361 \n <span class=\"match\">Eptifibatide</span> Injection, 2 mg/mL and 75 mg/100 mL \n USV Private Limited, U.S. Agent, Omega Pharmaceutical Consulting, Inc., 752 West Shuhthagi Lane, New Harmony, UT 84757. \n \n \n ANDA 204362 \n <span class=\"match\">Eptifibatide</span> Injection, 2 mg/mL \n Do. \n \n \n \n ANDA 204464 \n Sodium Fluoride F-18 Injection, 10-200 millicurie/mL \n Decatur Memorial Hospital, 2300 North Edward St., Suite 100, Decatur, IL"},{"title":"Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Short Inpatient Hospital Stays; Transition for Certain Medicare-Dependent, Small Rural Hospitals Under the Hospital Inpatient Prospective Payment System; Provider Administrative Appeals and Judicial Review","type":"Rule","abstract":"This final rule with comment period revises the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2016 to implement applicable statutory requirements and changes arising from our continuing experience with these systems. In this final rule with comment period, we describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. In addition, this final rule with comment period updates and refines the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program. Further, this document includes certain finalized policies relating to the hospital inpatient prospective payment system: Changes to the 2- midnight rule under the short inpatient hospital stay policy; and a payment transition for hospitals that lost their status as a Medicare- dependent, small rural hospital (MDH) because they are no longer in a rural area due to the implementation of the new Office of Management and Budget delineations in FY 2015 and have not reclassified from urban to rural before January 1, 2016. In addition, this document contains a final rule that finalizes certain 2015 proposals, and addresses public comments received, relating to the changes in the Medicare regulations governing provider administrative appeals and judicial review relating to appropriate claims in provider cost reports.","document_number":"2015-27943","html_url":"https://www.federalregister.gov/documents/2015/11/13/2015-27943/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2015-11-13/pdf/2015-27943.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2015-27943.pdf?1446236131","publication_date":"2015-11-13","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"payment methodology that applies to SCODs. The commenter also requested that, if CMS finalizes the proposal to package payment for the drug described by HCPCS code J0583 as a surgical supply, CMS should also package payment for the drugs described by HCPCS codes J1327 (<span class=\"match\">Eptifibatide</span>) and J3246 (Tirofiban hydrochloride) to ensure that the packaging policy is not implemented in an arbitrary and capricious manner.\n \n \n Response: \n We have previously explained why SCODs can be packaged in the OPPS (72 FR 66766). The drug described by HCPCS code J0583"},{"title":"Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates, the Ambulatory Surgical Center Payment System and CY 2008 Payment Rates, the Hospital Inpatient Prospective Payment System and FY 2008 Payment Rates; and Payments for Graduate Medical Education for Affiliated Teaching Hospitals in Certain Emergency Situations Medicare and Medicaid Programs: Hospital Conditions of Participation; Necessary Provider Designations of Critical Access Hospitals; Correction","type":"Rule","abstract":"This document corrects technical errors that appeared in the final rule with comment period published in the Federal Register (FR) on November 27, 2007, entitled \"Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates, the Ambulatory Surgical Center Payment System and CY 2008 Payment Rates, the Hospital Inpatient Prospective Payment System and FY 2008 Payment Rates; and Payments for Graduate Medical Education for Affiliated Teaching Hospitals in Certain Emergency Situations Medicare and Medicaid Programs: Hospital Conditions of Participation; Necessary Provider Designations of Critical Access Hospitals.\"","document_number":"08-671","html_url":"https://www.federalregister.gov/documents/2008/02/22/08-671/medicare-program-changes-to-the-hospital-outpatient-prospective-payment-system-and-cy-2008-payment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2008-02-22/pdf/08-671.pdf","public_inspection_pdf_url":null,"publication_date":"2008-02-22","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"\n J1270 \n Injection, doxercalciferol \n \n N1 \n \n \n \n \n J1300 \n Eculizumab injection \n NI \n K2 \n \n $176.38 \n \n \n J1320 \n Amitriptyline injection \n \n N1 \n \n \n \n \n J1324 \n Enfuvirtide injection \n \n K2 \n \n $0.40 \n \n \n J1325 \n Epoprostenol injection \n \n N1 \n \n \n \n \n J1327 \n <span class=\"match\">Eptifibatide</span> injection \n \n K2 \n \n $17.67 \n \n \n J1330 \n Ergonovine maleate injection \n CH \n N1 \n \n \n \n \n J1335 \n Ertapenem injection \n \n N1 \n \n \n \n \n J1364 \n Erythro lactobionate /500 MG \n \n N1 \n \n \n \n \n J1380 \n Estradiol valerate 10 MG inj \n \n N1 \n \n \n \n \n J1390 \n Estradiol valerate"},{"title":"Medicare Program: Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates, the Ambulatory Surgical Center Payment System and CY 2008 Payment Rates, the Hospital Inpatient Prospective Payment System and FY 2008 Payment Rates; and Payments for Graduate Medical Education for Affiliated Teaching Hospitals in Certain Emergency Situations Medicare and Medicaid Programs: Hospital Conditions of Participation; Necessary Provider Designations of Critical Access Hospitals","type":"Rule","abstract":"This final rule with comment period revises the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. We describe the changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes are applicable to services furnished on or after January 1, 2008. In addition, the rule sets forth the applicable relative payment weights and amounts for services furnished in ASCs, specific HCPCS codes to which the final policies of the ASC payment system apply, and other pertinent rate setting information for the CY 2008 ASC payment system. Furthermore, this final rule with comment period will make changes to the policies relating to the necessary provider designations of critical access hospitals and changes to several of the current conditions of participation requirements. The attached document also incorporates the changes to the FY 2008 hospital inpatient prospective payment system (IPPS) payment rates made as a result of the enactment of the TMA, Abstinence Education, and QI Programs Extension Act of 2007, Public Law 110-90. In addition, we are changing the provisions in our previously issued FY 2008 IPPS final rule and are establishing a new policy, retroactive to October 1, 2007, of not applying the documentation and coding adjustment to the FY 2008 hospital-specific rates for Medicare-dependent, small rural hospitals (MDHs) and sole community hospitals (SCHs). In the interim final rule with comment period in this document, we are modifying our regulations relating to graduate medical education (GME) payments made to teaching hospitals that have Medicare affiliation agreements for certain emergency situations.","document_number":"07-5507","html_url":"https://www.federalregister.gov/documents/2007/11/27/07-5507/medicare-program-changes-to-the-hospital-outpatient-prospective-payment-system-and-cy-2008-payment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2007-11-27/pdf/07-5507.pdf","public_inspection_pdf_url":null,"publication_date":"2007-11-27","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"($9000-$9500) \n T \n \n $9,250.00 \n \n $1,850.00 \n \n \n 1574 \n New Technology—Level XXXVII ($9500-$10000) \n T \n \n $9,750.00 \n \n $1,950.00 \n \n \n 1605 \n Abciximab injection \n K \n \n $420.17 \n \n $84.03 \n \n \n 1606 \n Injection anistreplase 30 u \n K \n \n $2,693.80 \n \n $538.76 \n \n \n 1607 \n <span class=\"match\">Eptifibatide</span> injection \n K \n \n $17.67 \n \n $3.53 \n \n \n 1608 \n Etanercept injection \n K \n \n $167.12 \n \n $33.42 \n \n \n 1609 \n Rho(D) immune globulin h, sd \n K \n \n $15.62 \n \n $3.12 \n \n \n 1612 \n Daclizumab, parenteral \n K \n \n $322.28 \n \n $64.46 \n \n \n 1613 \n Trastuzumab \n K \n \n $58.51 \n "},{"title":"Medicare Program: Proposed Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates; Proposed Changes to the Ambulatory Surgical Center Payment System and CY 2008 Payment Rates; Medicare and Medicaid Programs: Proposed Changes to Hospital Conditions of Participation; Proposed Changes Affecting Necessary Provider Designations of Critical Access Hospitals","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. In this proposed rule, we describe the proposed changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes would be applicable to services furnished on or after January 1, 2008. In addition, this proposed rule would update the revised Medicare ambulatory surgical center (ASC) payment system to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). In this proposed rule, we propose the applicable relative payment weights and amounts for services furnished in ASCs, specific HCPCS codes to which the final policies of the ASC payment system would apply, and other pertinent ratesetting information for the CY 2008 ASC payment system. These changes would be applicable to services furnished on or after January 1, 2008. In this proposed rule, we also are proposing changes to the policies relating to the necessary provider designations of critical access hospitals (CAHs) that are being recertified when a CAH enters into a new co-location arrangement with another hospital or CAH or when the CAH creates or acquires an off-campus location. Further, we are proposing changes to several of the current conditions of participation that hospitals must meet to participate in the Medicare and Medicaid programs to require the completion and documentation in the medical record of medical histories and physical examinations of patients conducted after admission and prior to surgery or a procedure requiring anesthesia services and for postanesthesia evaluations of patients before discharge or transfer from the postanesthesia recovery area.","document_number":"07-3509","html_url":"https://www.federalregister.gov/documents/2007/08/02/07-3509/medicare-program-proposed-changes-to-the-hospital-outpatient-prospective-payment-system-and-cy-2008","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2007-08-02/pdf/07-3509.pdf","public_inspection_pdf_url":null,"publication_date":"2007-08-02","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"T \n \n $9,250.00 \n \n $1,850.00 \n \n \n 1574 \n New Technology—Level XXXVII ($9500-$10000) \n T \n \n $9,750.00 \n \n $1,950.00 \n \n \n 1605 \n Abciximab injection \n K \n \n $409.26 \n \n $81.85 \n \n \n 1606 \n Injection anistreplase 30 u \n K \n 42.2935 \n $2,693.80 \n \n $538.76 \n \n \n 1607 \n <span class=\"match\">Eptifibatide</span> injection \n K \n \n $15.90 \n \n $3.18 \n \n \n 1608 \n Etanercept injection \n K \n \n $160.03 \n \n $32.01 \n \n \n 1609 \n Rho(D) immune globulin h, sd \n K \n \n $15.76 \n \n $3.15 \n \n \n 1612 \n Daclizumab, parenteral \n K \n \n $297.03 \n \n $59.41 \n \n \n 1613 \n Trastuzumab \n K \n \n $57.33 \n "},{"title":"Medicare Program; Revised Payment System Policies for Services Furnished in Ambulatory Surgical Centers (ASCs) Beginning in CY 2008","type":"Rule","abstract":"This final rule revises the Medicare ambulatory surgical center (ASC) payment system to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). This final rule establishes the ASC list of covered surgical procedures, identifies covered ancillary services under the revised ASC payment system, and sets forth the amounts and factors that will be used to determine the ASC payment rates for calendar year (CY) 2008. The changes to the ASC payment system and ratesetting methodology in this final rule are applicable to services furnished on or after January 1, 2008.","document_number":"07-3490","html_url":"https://www.federalregister.gov/documents/2007/08/02/07-3490/medicare-program-revised-payment-system-policies-for-services-furnished-in-ambulatory-surgical","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2007-08-02/pdf/07-3490.pdf","public_inspection_pdf_url":null,"publication_date":"2007-08-02","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"mesylate \n K2 \n \n $6.11 \n \n \n J1265 \n Dopamine injection \n N1 \n \n \n \n \n J1270 \n Injection, doxercalciferol \n N1 \n \n \n \n \n J1320 \n Amitriptyline injection \n N1 \n \n \n \n \n J1324 \n Enfuvirtide injection \n K2 \n \n $22.91 \n \n \n J1325 \n Epoprostenol injection \n N1 \n \n \n \n \n J1327 \n <span class=\"match\">Eptifibatide</span> injection \n K2 \n \n $16.05 \n \n \n J1330 \n Ergonovine maleate injection \n K2 \n \n $4.00 \n \n \n J1335 \n Ertapenem injection \n N1 \n \n \n \n \n J1364 \n Erythro lactobionate /500 MG \n N1 \n \n \n \n \n J1380 \n Estradiol valerate 10 MG inj \n N1 \n \n \n \n \n J1390 \n Estradiol valerate 20 MG"},{"title":"Medicare Program; Hospital Outpatient Prospective Payment System and CY 2007 Payment Rates; CY 2007 Update to the Ambulatory Surgical Center Covered Procedures List; Medicare Administrative Contractors; and Reporting Hospital Quality Data for FY 2008 Inpatient Prospective Payment System Annual Payment Update Program-HCAHPS Survey, SCIP, and Mortality","type":"Rule","abstract":"This final rule with comment period revises the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system, and to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 and the Deficit Reduction Act (DRA) of 2005. In this final rule with comment period, we describe changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes are applicable to services furnished on or after January 1, 2007. In addition, this final rule with comment period implements future CY 2009 required reporting on quality measures for hospital outpatient services paid under the prospective payment system. This final rule with comment period revises the current list of procedures that are covered when furnished in a Medicare-approved ambulatory surgical center (ASC), which are applicable to services furnished on or after January 1, 2007. This final rule with comment period revises the emergency medical screening requirements for critical access hospitals (CAHs). This final rule with comment period supports implementation of a restructuring of the contracting entities responsibilities and functions that support the adjudication of Medicare fee-for-service (FFS) claims. This restructuring is directed by section 1874A of the Act, as added by section 911 of the MMA. The prior separate Medicare intermediary and Medicare carrier contracting authorities under Title XVIII of the Act have been replaced with the Medicare Administrative Contractor (MAC) authority. This final rule continues to implement the requirements of the DRA that require that we expand the \"starter set\" of 10 quality measures that we used in FY 2005 and FY 2006 for the hospital inpatient prospective payment system (IPPS) Reporting Hospital Quality Data for the Annual Payment Update (RHQDAPU) program. We began to adopt expanded measures effective for payments beginning in FY 2007. In this rule, we are finalizing additional quality measures for the expanded set of measures for FY 2008 payment purposes. These measures include the HCAHPS survey, as well as Surgical Care Improvement Project (SCIP, formerly Surgical Infection Prevention (SIP)), and Mortality quality measures.","document_number":"06-9079","html_url":"https://www.federalregister.gov/documents/2006/11/24/06-9079/medicare-program-hospital-outpatient-prospective-payment-system-and-cy-2007-payment-rates-cy-2007","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2006-11-24/pdf/06-9079.pdf","public_inspection_pdf_url":null,"publication_date":"2006-11-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"1,950.00 \n \n \n 1600 \n Tc99m sestamibi \n H \n \n \n \n \n \n \n 1603 \n TL201 thallium \n H \n \n \n \n \n \n \n 1604 \n In111 capromab \n H \n \n \n \n \n \n \n 1605 \n Abciximab injection \n K \n \n 416.27 \n \n 83.25 \n \n \n 1606 \n Injection anistreplase 30 u \n K \n \n 2,268.46 \n \n 453.69 \n \n \n 1607 \n <span class=\"match\">Eptifibatide</span> injection \n K \n \n 15.37 \n \n 3.07 \n \n \n 1608 \n Etanercept injection \n K \n \n 160.39 \n \n 32.08 \n \n \n 1609 \n Rho(D) immune globulin h, sd \n K \n \n 14.30 \n \n 2.86 \n \n \n 1612 \n Daclizumab, parenteral \n K \n \n 328.83 \n \n 65.77 \n \n \n 1613 \n Trastuzumab \n K \n \n 56.17 \n \n 11.23 \n"},{"title":"Medicare Program; Hospital Outpatient Prospective Payment System and CY 2007 Payment Rates; CY 2007 Update to the Ambulatory Surgical Center Covered Procedures List; Ambulatory Surgical Center Payment System and CY 2008 Payment Rates; Medicare Administrative Contractors; and Reporting Hospital Quality Data for FY 2008 Inpatient Prospective Payment System Annual Payment Update Program-HCAHPS® Survey, SCIP, and Mortality","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system, and to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003, and the Deficit Reduction Act (DRA) of 2005. The proposed rule describes proposed changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes would be applicable to services furnished on or after January 1, 2007. In addition, this proposed rule would revise the current list of procedures that are approved when furnished in a Medicare-approved ambulatory surgical center (ASC), which would be applicable to services furnished on or after January 1, 2007. Further, this proposed rule would revise the ASC facility payment system to implement provisions of the MMA and other applicable statutory requirements, and update the ASC payment rates. Changes to the ASC facility payment system and the payment rates would be applicable to services furnished on or after January 1, 2008. This proposed rule would revise the emergency medical screening requirements for critical access hospitals (CAHs). In addition, this proposed rule would support implementation of a restructuring of the contracting entities responsibilities and functions that support the adjudication of Medicare fee-for-service (FFS) claims. This restructuring is directed by section 1874A of the Act, as added by section 911 of the MMA. The prior separate Medicare intermediary and Medicare carrier contracting authorities under Title XVIII of the Act have been replaced with the Medicare Administrative Contractor (MAC) authority. This proposed rule would also continue to implement the requirements of the DRA that require that we expand the \"starter set\" of 10 quality measures that we used in FY 2005 and FY 2006 for the hospital Inpatient Prospective Payment System (IPPS) Reporting Hospital Quality Data for the Annual Payment Update (RHQDAPU) program. We began to adopt expanded measures effective for payments beginning in FY 2007. We are proposing to add additional quality measures to the expanded set of measures for FY 2008 payment purposes. These measures include the HCAHPS[supreg] survey, as well as Surgical Care Improvement Project (SCIP, formerly Surgical Infection Prevention (SIP)), and Mortality quality measures.","document_number":"06-6846","html_url":"https://www.federalregister.gov/documents/2006/08/23/06-6846/medicare-program-hospital-outpatient-prospective-payment-system-and-cy-2007-payment-rates-cy-2007","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2006-08-23/pdf/06-6846.pdf","public_inspection_pdf_url":null,"publication_date":"2006-08-23","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"\n K \n \n 82.58 \n \n 16.52 \n \n \n 1603 \n TL201 thallium \n K \n \n 27.18 \n \n 5.44 \n \n \n 1604 \n In111 capromab \n K \n \n 928.19 \n \n 185.64 \n \n \n 1605 \n Abciximab injection \n K \n \n 452.96 \n \n 90.59 \n \n \n 1606 \n Injection anistreplase 30 u \n K \n \n 2,265.46 \n \n 453.09 \n \n \n 1607 \n <span class=\"match\">Eptifibatide</span> injection \n K \n \n 13.31 \n \n 2.66 \n \n \n 1608 \n Etanercept injection \n K \n \n 154.12 \n \n 30.82 \n \n \n 1609 \n Rho(D) immune globulin h, sd \n K \n \n 13.57 \n \n 2.71 \n \n \n 1611 \n Hylan G-F 20 injection \n K \n \n 196.99 \n \n 39.40 \n \n \n 1612 \n Daclizumab, parenteral \n K \n \n 345.07"},{"title":"Medicare Program; Proposed Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2006 Payment Rates; Correction","type":"Proposed Rule","abstract":"This document corrects technical errors that appeared in the proposed rule published in the Federal Register on July 25, 2005 entitled \"Medicare Program; Proposed Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2006 Payment Rates; Proposed Rule.\"","document_number":"05-16699","html_url":"https://www.federalregister.gov/documents/2005/08/26/05-16699/medicare-program-proposed-changes-to-the-hospital-outpatient-prospective-payment-system-and-calendar","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2005-08-26/pdf/05-16699.pdf","public_inspection_pdf_url":null,"publication_date":"2005-08-26","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"\n T \n \n $9,750.00 \n \n $1,950.00 \n \n \n 1600 \n Technetium TC 99m sestamibi \n H \n \n \n \n \n \n \n 1603 \n Thallous chloride TL 201 \n H \n \n \n \n \n \n \n 1604 \n IN 111 capromab pendetide, per dose \n H \n \n \n \n \n \n \n 1605 \n Abciximab injection \n K \n \n $450.60 \n \n $90.12 \n \n \n 1607 \n <span class=\"match\">Eptifibatide</span> injection \n K \n \n $12.73 \n \n $2.55 \n \n \n 1608 \n Etanercept injection \n K \n \n $152.11 \n \n $30.42 \n \n \n 1609 \n Rho(D) immune globulin h, sd \n K \n \n $12.04 \n \n $2.41 \n \n \n 1611 \n Hylan G-F 20 injection \n K \n \n $203.15 \n \n $40.63 \n \n \n 1612 \n Daclizumab, parenteral \n K \n "},{"title":"Medicare Program; Proposed Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2006 Payment Rates","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system and to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003. In addition, the proposed rule describes proposed changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. This proposed rule would also change the requirement for physician oversight of mid-level practitioners in critical access hospitals (CAHs). These changes would be applicable to services furnished on or after January 1, 2006.","document_number":"05-14448","html_url":"https://www.federalregister.gov/documents/2005/07/25/05-14448/medicare-program-proposed-changes-to-the-hospital-outpatient-prospective-payment-system-and-calendar","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2005-07-25/pdf/05-14448.pdf","public_inspection_pdf_url":null,"publication_date":"2005-07-25","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"\n T \n \n $9,750.00 \n \n $1,950.00 \n \n \n 1600 \n Technetium TC 99m sestamibi \n H \n \n \n \n \n \n \n 1603 \n Thallous chloride TL 201 \n H \n \n \n \n \n \n \n 1604 \n IN 111 capromab pendetide, per dose \n H \n \n \n \n \n \n \n 1605 \n Abciximab injection \n K \n \n $450.56 \n \n $90.11 \n \n \n 1607 \n <span class=\"match\">Eptifibatide</span> injection \n K \n \n $12.73 \n \n $2.55 \n \n \n 1608 \n Etanercept injection \n K \n \n $152.10 \n \n $30.42 \n \n \n 1609 \n Rho(D) immune globulin h, sd \n K \n \n $12.04 \n \n $2.41 \n \n \n 1611 \n Hylan G-F 20 injection \n K \n \n $203.13 \n \n $40.63 \n \n \n 1612 \n Daclizumab, parenteral \n K \n "},{"title":"Medicare Program; Hospital Outpatient Prospective Payment System; Payment Reform for Calendar Year 2004","type":"Rule","abstract":"This interim final rule with comment period implements provisions of the Medicare Prescription Drug, Improvement, and Modernization Act (DIMA) of 2003 that affect the Medicare outpatient prospective payment system (OPPS) that become effective January 1, 2004. Sections 303 and 621 of the DIMA include provisions that alter the methods for drug payment in hospital outpatient departments, some of which become effective January 1, 2004. These provisions affect the methodology for paying for pass-through and non-pass-through drugs under the OPPS. Further, the new law includes a requirement that all brachytherapy sources be paid separately. Section 411 of the DIMA reinstates the hold-harmless protection for small rural hospitals with fewer than 100 beds and extends that protection to sole community hospitals in rural areas.","document_number":"03-32322","html_url":"https://www.federalregister.gov/documents/2004/01/06/03-32322/medicare-program-hospital-outpatient-prospective-payment-system-payment-reform-for-calendar-year","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2004-01-06/pdf/03-32322.pdf","public_inspection_pdf_url":null,"publication_date":"2004-01-06","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"J0585 \n K \n Botulinum toxin a per unit \n 0902 \n 3.21 \n 4.58 \n \n \n J0587 \n K \n Botulinum toxin type B \n 9018 \n 6.98 \n 8.14 \n \n \n J0637 \n K \n Caspofungin acetate \n 9019 \n 29.64 \n 30.52 \n \n \n J0850 \n K \n Cytomegalovirus imm IV /vial \n 0903 \n 291.18 \n 659.60 \n \n \n J1327 \n K \n <span class=\"match\">Eptifibatide</span> injection \n 1607 \n 7.99 \n 11.88 \n \n \n J1438 \n K \n Etanercept injection \n 1608 \n 102.37 \n 143.73 \n \n \n J1440 \n K \n Filgrastim 300 mcg injection \n 0728 \n 123.48 \n 172.20 \n \n \n J1441 \n K \n Filgrastim 480 mcg injection \n 7049 \n 175.96 \n 290.93 \n \n \n J1565 \n K \n RSV-ivig \n"},{"title":"Medicare Program; Payment Reform for Part B Drugs","type":"Proposed Rule","abstract":"This proposed rule would revise, based on one of four approaches, the current payment methodology for Part B covered drugs and biologicals that are not paid on a cost or prospective payment basis. We are seeking comments on which of these proposed approaches we should implement. This proposed rule would also make changes to Medicare payment for furnishing or administering certain drugs and biologicals.","document_number":"03-21308","html_url":"https://www.federalregister.gov/documents/2003/08/20/03-21308/medicare-program-payment-reform-for-part-b-drugs","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2003-08-20/pdf/03-21308.pdf","public_inspection_pdf_url":null,"publication_date":"2003-08-20","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"INJECTION, DOBUTAMINE HYDROCHLORIDE, PER 250 MG \n \n \n J1260 \n INJECTION, DOLASETRON MESYLATE, 10 MG \n \n \n J1270 \n INJECTION, DOXERCALCIFEROL, 1 MCG \n \n \n J1320 \n INJECTION, AMITRIPTYLINE HCL, UP TO 20 MG \n \n \n J1325 \n INJECTION, EPOPROSTENOL, 0.5 MG \n \n \n J1327 \n INJECTION, <span class=\"match\">EPTIFIBATIDE</span>, 5 MG \n \n \n J1364 \n INJECTION, ERYTHROMYCIN LACTOBIONATE, PER 500 MG \n \n \n J1380 \n INJECTION, ESTRADIOL VALERATE, UP TO 10 MG \n \n \n J1390 \n INJECTION, ESTRADIOL VALERATE, UP TO 20 MG \n \n \n J1410 \n INJECTION, ESTROGEN CONJUGATED, PER 25 MG \n \n \n J1435 \n INJECTION, ESTRONE"},{"title":"Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2004 Payment Rates","type":"Rule","abstract":"This final rule with comment period revises the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. In addition, it describes changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes are applicable to services furnished on or after January 1, 2004. Finally, this rule responds to public comments received on the August 12, 2003 proposed rule for revisions to the hospital outpatient prospective payment system and payment rates (68 FR 47966).","document_number":"03-27791","html_url":"https://www.federalregister.gov/documents/2003/11/07/03-27791/medicare-program-changes-to-the-hospital-outpatient-prospective-payment-system-and-calendar-year","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2003-11-07/pdf/03-27791.pdf","public_inspection_pdf_url":null,"publication_date":"2003-11-07","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"0.3645 \n $19.89 \n \n $3.98 \n \n \n 1604 \n IN 111 capromab pendetide, per dose \n K \n 12.6045 \n $687.71 \n \n $137.54 \n \n \n 1605 \n Abciximab injection, 10 mg \n K \n 5.3048 \n $289.44 \n \n $57.89 \n \n \n \n 1606 \n Anistreplase, 30 u \n K \n 27.7939 \n $1,516.46 \n \n $303.29 \n \n \n 1607 \n <span class=\"match\">Eptifibatide</span> injection, 5mg \n K \n 0.1465 \n $7.99 \n \n $1.60 \n \n \n 1608 \n Etanercept injection \n K \n 1.8762 \n $102.37 \n \n $20.47 \n \n \n 1609 \n Rho(D) immune globulin h, sd, 100 iu \n K \n 0.1789 \n $9.76 \n \n $1.95 \n \n \n 1611 \n Hylan G-F 20 injection, 16 mg \n K \n 2.2628 \n $123.46 \n \n $24"},{"title":"Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2004 Payment Rates","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. In addition, it would describe proposed changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes would be applicable to services furnished on or after January 1, 2004.","document_number":"03-20280","html_url":"https://www.federalregister.gov/documents/2003/08/12/03-20280/medicare-program-changes-to-the-hospital-outpatient-prospective-payment-system-and-calendar-year","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2003-08-12/pdf/03-20280.pdf","public_inspection_pdf_url":null,"publication_date":"2003-08-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":" \n $9,750.00 \n \n $1,950.00 \n \n \n 1604 \n IN 111 capromab pendetide, per dose \n K \n 12.4029 \n $673.34 \n \n $134.67 \n \n \n 1605 \n Abciximab injection, 10 mg \n K \n 5.2806 \n $286.68 \n \n $57.34 \n \n \n 1606 \n Anistreplase, 30 u \n K \n 25.3116 \n $1,374.14 \n \n $274.83 \n \n \n 1607 \n <span class=\"match\">Eptifibatide</span> injection, 5mg \n K \n 0.1426 \n $7.74 \n \n $1.55 \n \n \n 1609 \n Rho(D) immune globulin h, sd, 100 iu \n K \n 0.1863 \n $10.11 \n \n $2.02 \n \n \n 1611 \n Hylan G-F 20 injection, 16 mg \n K \n 2.1566 \n $117.08 \n \n $23.42 \n \n \n 1612 \n Daclizumab, parenteral, 25 mg \n K \n 3.7304 \n $202.52"},{"title":"Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2003 Payment Rates; and Changes to Payment Suspension for Unfiled Cost Reports; Correction","type":"Rule","abstract":"This document corrects errors that appeared in the final rule with comment period published in the Federal Register on November 1, 2002, entitled \"Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2003 Payment Rates; and Changes to Payment Suspension for Unfiled Cost Reports.\" This notice is a supplement to the November 1, 2002, final rule with comment period and to the November 15, 2002, correction notice, which added section \"XVI. Waiver of Proposed Rulemaking.\"","document_number":"03-2789","html_url":"https://www.federalregister.gov/documents/2003/02/10/03-2789/medicare-program-changes-to-the-hospital-outpatient-prospective-payment-system-and-calendar-year","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2003-02-10/pdf/03-2789.pdf","public_inspection_pdf_url":null,"publication_date":"2003-02-10","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"insert a relative weight of 3.8662, payment rate of $201.63, and minimum unadjusted copayment of $40.33. \n As a result of a technical recalculation to <span class=\"match\">Eptifibatide</span> Injection, CPT/HCPCS code J1327, the median cost for this drug exceeds the threshold used for determining whether a drug qualifies for a separate APC. To reflect this change, on page 66821, insert APC 1607, group title of <span class=\"match\">Eptifibatide</span> Injection, 5 mg, status indictor of K, relative weight of 0.1453, payment rate of $7.58, minimum unadjusted copayment of $1.52. \n On page 66821, under APC"},{"title":"Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2003 Payment Rates; and Changes to Payment Suspension for Unfiled Cost Reports","type":"Rule","abstract":"This final rule with comment period revises the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. In addition, it describes changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes are applicable to services furnished on or after January 1, 2003. This rule also allows the Secretary to suspend Medicare payments \"in whole or in part\" if a provider fails to file a timely and acceptable cost report. In addition, this rule responds to public comments received on the November 2, 2001 interim final rule with comment period (66 FR 55850) that set forth the criteria the Secretary will use to establish new categories of medical devices eligible for transitional pass-through payment under the Medicare's hospital outpatient prospective payment system. Finally, this rule responds to public comments received on the August 9, 2002 proposed rule for revisions to the hospital outpatient prospective payment system and payment rates (67 FR 52092). CMS finds good cause to waive proposed rulemaking for the assignment of new codes to Ambulatory Payment Classifications and for the payment of influenza and pneuomococcal vaccines under reasonable cost; justification for the waiver will follow in a subsequent Federal Register notice.","document_number":"02-27548","html_url":"https://www.federalregister.gov/documents/2002/11/01/02-27548/medicare-program-changes-to-the-hospital-outpatient-prospective-payment-system-and-calendar-year","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2002-11-01/pdf/02-27548.pdf","public_inspection_pdf_url":null,"publication_date":"2002-11-01","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"Inj dobutamine HCL/250 mg \n \n \n \n \n \n \n \n J1260 \n N \n \n Dolasetron mesylate \n \n \n \n \n \n \n \n \n J1270 \n N \n \n Injection, doxercalciferol \n \n \n \n \n \n \n \n J1320 \n N \n \n Amitriptyline injection \n \n \n \n \n \n \n \n J1325 \n N \n \n Epoprostenol injection \n \n \n \n \n \n \n \n J1327 \n N \n \n <span class=\"match\">Eptifibatide</span> injection \n \n \n \n \n \n \n \n J1330 \n N \n \n Ergonovine maleate injection \n \n \n \n \n \n \n \n J1364 \n N \n \n Erythro lactobionate /500 MG \n \n \n \n \n \n \n \n J1380 \n N \n \n Estradiol valerate 10 MG inj \n \n \n \n \n \n \n \n J1390 \n N \n \n Estradiol valerate 20 MG inj \n \n \n \n \n \n \n \n J1410 "},{"title":"Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2003 Payment Rates; and Changes to Payment Suspension for Unfiled Cost Reports","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. In addition, it would describe proposed changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes would be applicable to services furnished on or after January 1, 2003. In addition, this rule proposes to allow the Secretary to suspend Medicare payments \"in whole or in part\" if a provider fails to file a timely and acceptable cost report.","document_number":"02-20146","html_url":"https://www.federalregister.gov/documents/2002/08/09/02-20146/medicare-program-changes-to-the-hospital-outpatient-prospective-payment-system-and-calendar-year","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2002-08-09/pdf/02-20146.pdf","public_inspection_pdf_url":null,"publication_date":"2002-08-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"Injection adenosine 6 MG \n \n \n J0350 \n Injection anistreplase 30 u \n \n \n J0640 \n Leucovorin calcium injection \n \n \n J0706 \n Caffeine Citrate, inj, per 5 mg \n \n \n J1245 \n Dipyridamole injection \n \n \n J1260 \n Dolasetron mesylate \n \n \n J1325 \n Epoprostenol injection \n \n \n J1327 \n <span class=\"match\">Eptifibatide</span> injection \n \n \n J1436 \n Etidronate disodium inj \n \n \n J1438 \n Etanercept injection \n \n \n J1565 \n RSV-ivig \n \n \n J1570 \n Ganciclovir sodium injection \n \n \n J1620 \n Gonadorelin hydroch/ 100 mcg \n \n \n J1626 \n Granisetron HCl injection \n \n \n J1670 \n Tetanus immune globulin"},{"title":"Medicare Program; Correction of Certain Calendar Year 2002 Payment Rates Under the Hospital Outpatient Prospective Payment System and the Pro Rata Reduction on Transitional Pass-Through Payments; Correction of Technical and Typographical Errors","type":"Rule","abstract":"This final rule corrects inadvertent technical errors that affect the amounts and factors used to determine the payment rates for services paid under the Medicare hospital outpatient prospective payment system as published in the November 30, 2001 final rule entitled \"Changes to the Hospital Outpatient Prospective Payment System for Calendar Year 2002.\" In addition, this final rule corrects the amount of the uniform reduction to be applied to transitional pass- through payments for CY 2002. This final rule also corrects other technical and typographical errors that appeared in the November 30, 2001 final rule.","document_number":"02-5071","html_url":"https://www.federalregister.gov/documents/2002/03/01/02-5071/medicare-program-correction-of-certain-calendar-year-2002-payment-rates-under-the-hospital","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2002-03-01/pdf/02-5071.pdf","public_inspection_pdf_url":null,"publication_date":"2002-03-01","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"chloride TL 201, per mCi \n G \n \n $78.16 \n \n $7.08 \n \n \n 1604 \n IN 111 capromab pendetide, per dose \n G \n \n $2,192.13 \n \n $313.82 \n \n \n 1605 \n Abciximab injection, 10 mg \n G \n \n $513.02 \n \n $73.44 \n \n \n 1606 \n Anistreplase, 30 u \n G \n \n $2,693.80 \n \n $385.64 \n \n \n 1607 \n <span class=\"match\">Eptifibatide</span> injection, 5 mg \n G \n \n $11.31 \n \n $1.45 \n \n \n 1608 \n Etanercept injection, 25 mg \n G \n \n $141.01 \n \n $20.19 \n \n \n 1609 \n Rho(D) immune globulin h, sd, 100 iu \n G \n \n $20.55 \n \n $2.64 \n \n \n 1611 \n Hylan G-F 20 injection, 16 mg \n G \n \n $213.87 \n \n $27.47 \n \n \n 1612 \n Daclizumab"}]}